- Hypercholesterolaemic particpants were analyzed during this double-blinded, randomised, placebo-controlled, 2 × 2 factorial trial.
- Candidates received either placebo (PL, no phytosterols or curcumin), phytosterols (PS, 2 g/d), curcumin (CC, 200 mg/d) or a combination of PS and curcumin (PS-CC, 2 g/d-200 mg/d respectively) for four weeks.
- Fasting total cholesterol (TC), LDL-cholesterol, HDL-cholesterol, triglycerides (TG), TC-to-HDL-C ratio (TC:HDL-C) were included as the primary outcomes.
- Anthropometrics and fasting blood glucose concentrations served as the secondary outcomes.
- This research was completed by 70 subjects, with a mean (±SEM) fasting TC concentration of 6.57 ± 0.13 mmol/L (PL, n = 18; PS, n = 17; CC, n = 18; PS-CC, n = 17).
- A prominent lowering of TC, LDL-cholesterol and TC:HDL-C post-intervention (p < 0.05) was achieved by PS and PS-CC supplementation.
- It was determined that the reductions from baseline in the PS group were 4.8% and 8.1% for TC and LDL-cholesterol respectively (p < 0.05).
- Non-significant reduction (2.3% and 2.6%) was illustrated in TC and LDL-C respectively by CC.
- Nevertheless, the PS-CC gave rise to a greater reduction in TC (11.0%) and LDL-cholesterol (14.4%) when compared to either of the treatments alone (p < 0.0001).
- A substantially greater reduction was yielded in the PS-CC treatment compared to those for CC (p < 0.05) or PL (p < 0.01) alone.
- Across all groups, plasma HDL-cholesterol and TG concentrations did not alter.
- Findings did not disclose any adverse side effects.